Cognitive impairment in patients with coronavirus infection
https://doi.org/10.14412/2074-2711-2022-4-96-102
Abstract
The pathogenesis of the development of cognitive impairment (CI) associated with the SARS-CoV-2 virus is complex and includes the direct neurotoxic effect of the virus, vascular, disimmune factors, artificial lung ventilation, and adverse psychological consequences of social isolation. The relationship between CI and SARS-CoV-2 infection appears to be two-way: patients with premorbid CI have a higher risk of infection, severe illness, and death; on the other hand, past infection with SARS-CoV-2 may stimulate the clinical onset and progression of CI, including Alzheimer's disease. For the treatment of severe CI after COVID-19, memantine (akatinol memantine) is recommended.
Supporting agencies: This article has been supported by Merz Pharma.
About the Authors
Y. A. Starchina
Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Yulia Aleksandrovna Starchina
119021, Moscow, Rossolimo St., 11, Build. 1
Competing Interests:
The conflict of interest has not affected the results of the investigation.
O. V. Kosivtsova
Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
119021, Moscow, Rossolimo St., 11, Build. 1
Competing Interests:
The conflict of interest has not affected the results of the investigation.
References
1. World Health Organization. Available from: https://covid19.who.int/ (accessed 01.07.2022).
2. Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun;20(6):363-74. doi:10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
3. Thakur B, Dubey P, Benitez J, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021 Apr 20;11(1):8562. doi:10.1038/s41598-021-88130-w
4. Bianchetti A, Rozzini R, Guerini F, et al. Clinical Presentation of COVID19 in Dementia Patients. J Nutr Health Aging. 2020;24(6):560-2. doi:10.1007/s12603-020-1389-1
5. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020 Jul;87:18-22. doi:10.1016/j.bbi.2020.03.031. Epub 2020 Mar 30.
6. Toniolo S, Scarioni M, Di Lorenzo F, et al; Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel. Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care. J Alzheimers Dis. 2021;82(3):883-98. doi:10.3233/JAD-210335
7. Zhou J, Liu C, Sun Y, et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021 Jan;91:383-92. doi:10.1016/j.bbi.2020.10.019. Epub 2020 Oct 24.
8. Chang TS, Ding Y, Freund MK, et al; UCLA Health Data Mart Working Group. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System. medRxiv [Preprint]. 2020 Jul 9:2020.07.03.20145581. doi:10.1101/2020.07.03.20145581
9. Herman C, Mayer K, Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology. 2020 Jul 14;95(2):77-84. doi:10.1212/WNL.0000000000009673. Epub 2020 Apr 28.
10. Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-30. doi:10.1093/gerona/glaa183
11. Azarpazhooh MR, Amiri A, Morovatdar N, et al. Correlations between COVID-19 and burden of dementia: An ecological study and review of literature. J Neurol Sci. 2020 Sep 15;416:117013. doi:10.1016/j.jns.2020.117013. Epub 2020 Jul 4.
12. Suarez-Gonzalez A et al. Impact and mortality of COVID-19 on people living with dementia: Cross-country report. 2020. Available from: https://ltccovid.org/wp-content/uploads/2020/08/International-report-onthe-impact-of-COVID-19-on-people-livingwith-dementia-19-August-2020.pdf
13. Kuo CL, Pilling LC, Atkins JL, et al. ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1801-3. doi:10.1093/gerona/glaa169
14. Cesari M, Proietti M. COVID-19 in Italy: Ageism and Decision Making in a Pandemic. J Am Med Dir Assoc. 2020 May;21(5):576-7. doi:10.1016/j.jamda.2020.03.025. Epub 2020 Apr 1.
15. Alzheimer Europe. Alzheimer Europe position regarding the allocation of scarce medical resources for intensive care services during the COVID-19 pandemic. 2020. Available from: https://www.ceafa.es/files/2020/04/2020-intensive-care-services-during-covid-19-1.pdf
16. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020 Sep;19(9):767-83. doi:10.1016/S1474-4422(20)30221-0. Epub 2020 Jul 2.
17. Varatharaj A, Thomas N, Ellul MA, et al; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82. doi:10.1016/S2215-0366(20)30287-X. Epub 2020 Jun 25. Erratum in: Lancet Psychiatry. 2020 Jul 14.
18. Alonso-Lana S, Marquie M, Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020 Oct 26;12:588872. doi:10.3389/fnagi.2020.588872
19. Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline. J Neurol Sci. 2020 Aug 15;415:116969. doi:10.1016/j.jns.2020.116969. Epub 2020 Jun 3.
20. Zarifkar P, Peinkhofer C, Benros ME, Kondziella D. Frequency of Neurological Diseases After COVID-19, Influenza A/B and Bacterial Pneumonia. Front Neurol. 2022 Jun 23;13:904796. doi:10.3389/fneur.2022.904796
21. Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Mol Neurobiol. 2021 Mar;58(3):1017-23. doi:10.1007/s12035-020-02177-w. Epub 2020 Oct 19.
22. Ding Q, Shults NV, Gychka SG, et al. Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease. Int J Mol Sci. 2021 Feb 8;22(4):1687. doi:10.3390/ijms22041687
23. Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. JAMA Neurol. 2020 Aug 1;77(8):1028-9. doi:10.1001/jamaneurol.2020.2125
24. Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020 Aug 1;77(8):1018-27. doi:10.1001/jamaneurol.2020.2065
25. Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020 Jun;20(6):351. doi:10.1038/s41577-020-0317-2
26. Fenrich M, Mrdenovic S, Balog M, et al. SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury. Front Cell Neurosci. 2020 Aug 5;14:229. doi:10.3389/fncel.2020.00229
27. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020 Nov;16(11):636-44. doi:10.1038/s41582-020-0398-3. Epub 2020 Aug 24.
28. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020 Nov;19(11):919-29. doi:10.1016/S1474-4422(20)30308-2. Epub 2020 Oct 5.
29. Pensato U, Muccioli L, Cani I, et al. Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy. Ann Clin Transl Neurol. 2021 Apr;8(4):968-79. doi:10.1002/acn3.51348. Epub 2021 Mar 29.
30. Meneses G, Cardenas G, Espinosa A, et al. Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury. Ann N Y Acad Sci. 2019 Feb;1437(1):43-56. doi:10.1111/nyas.13985. Epub 2018 Nov 29.
31. Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021 Jan;28(1):248-58. doi:10.1111/ene.14491. Epub 2020 Oct 5.
32. Aceti A, Margarucci LM, Scaramucci E, et al. Serum S100B protein as a marker of severity in COVID-19 patients. Sci Rep. 2020 Oct 29;10(1):18665. doi:10.1038/s41598-020-75618-0
33. Pilotto A, Masciocchi S, Volonghi I, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin Infect Dis. 2021 Nov 2;73(9):e3019-e3026. doi:10.1093/cid/ciaa1933
34. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi:10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.
35. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi:10.1186/s40779-020-00240-0
36. Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013 Feb;9(2):106-18. doi:10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Erratum in: Nat Rev Neurol. 2013. doi:10.1038/nmeurol.2013.32
37. Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2. doi:10.1093/gerona/glaa131
38. Motta C, Finardi A, Toniolo S, et al. Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. J Alzheimers Dis. 2020;76(2):681-9. doi:10.3233/JAD-191250
39. Li J, Long X, Huang H, et al. Resilience of Alzheimer's Disease to COVID-19. J Alzheimers Dis. 2020;77(1):67-73. doi:10.3233/JAD-200649
40. Kurki SN, Kantonen J, Kaivola K, et al. APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathol Commun. 2021 Dec 23;9(1):199. doi:10.1186/s40478-021-01302-7
41. Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014 Oct;50(2):534-44. doi:10.1007/s12035-014-8657-1. Epub 2014 Feb 25.
42. Rachal Pugh C, Fleshner M, Watkins LR, et al. The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev. 2001 Jan;25(1):29-41. doi:10.1016/s0149-7634(00)00048-8
43. Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996 SepOct;17(5):761-6. doi:10.1016/0197-4580(96)00104-2
44. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006378. doi:10.1002/14651858.CD006378.pub2
45. Cani I, Barone V, D'Angelo R, et al. Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol. 2021 Jan;268(1):16-9. doi:10.1007/s00415-020-10057-5. Epub 2020 Jul 11.
46. Delorme C, Paccoud O, Kas A, et al; CoCo-Neurosciences study group and COVID SMIT PSL study group. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020 Dec;27(12):2651-7. doi:10.1111/ene.14478. Epub 2020 Sep 22.
47. Kas A, Soret M, Pyatigoskaya N, et al; on the behalf of CoCo-Neurosciences study group and COVID SMIT PSL study group. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2543-57. doi:10.1007/s00259-020-05178-y. Epub 2021 Jan 15. Erratum in: Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3304.
48. Toniolo S, Di Lorenzo F, Scarioni M, et al. Is the Frontal Lobe the Primary Target of SARS-CoV-2? J Alzheimers Dis. 2021;81(1):75-81. doi:10.3233/JAD-210008
49. Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Jun 4;382(23):2268-70. doi:10.1056/NEJMc2008597. Epub 2020 Apr 15.
50. Muccioli L, Pensato U, Cani I, et al. COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation. Ann Neurol. 2020 Oct;88(4):860-1. doi:10.1002/ana.25855. Epub 2020 Aug 14.
51. Beaud V, Crottaz-Herbette S, Dunet V, et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-8. doi:10.1136/jnnp-2020-325173. Epub 2020 Nov 20.
52. Antony AR, Haneef Z. Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. 2020 Dec;83:234-41. doi:10.1016/j.seizure.2020.10.014. Epub 2020 Oct 19.
53. Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, et al. 18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. Acad Radiol. 2020 Jul;27(7):1042-3. doi:10.1016/j.acra.2020.04.030. Epub 2020 May 3.
54. O'Reilly RC. The What and How of prefrontal cortical organization. Trends Neurosci. 2010 Aug;33(8):355-61. doi:10.1016/j.tins.2010.05.002. Epub 2010 Jun 22.
55. Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020 Oct;129:98-102. doi:10.1016/j.jpsychires.2020.06.022. Epub 2020 Jun 30.
56. Vintimilla R, Hall J, Johnson L, O'Bryant S. The relationship of CRP and cognition in cognitively normal older Mexican Americans: A cross-sectional study of the HABLE cohort. Medicine (Baltimore). 2019 May;98(19):e15605. doi:10.1097/MD.0000000000015605
57. Chiricosta L, Gugliandolo A, Mazzon E. SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer's Disease Patients. Int J Mol Sci. 2021 Dec 19;22(24):13603. doi:10.3390/ijms222413603
58. Harker RC, Priemer DS. Beta-Amyloid Deposits in Young COVID Patients. Available from: https://ssrn.com/abstract=4003213 (accessed 25.04.2022).
59. Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020 Mar 6;17(5):1729. doi:10.3390/ijerph17051729
60. Amjad H, Roth DL, Samus QM, et al. Potentially Unsafe Activities and Living Conditions of Older Adults with Dementia. J Am Geriatr Soc. 2016 Jun;64(6):1223-32. doi:10.1111/jgs.14164. Epub 2016 Jun 2.
61. Ammar A, Boukhris O, Halfpaap N, et al. Four Weeks of Detraining Induced by COVID-19 Reverse Cardiac Improvements from Eight Weeks of Fitness-Dance Training in Older Adults with Mild Cognitive Impairment. Int J Environ Res Public Health. 2021 May 31;18(11):5930. doi:10.3390/ijerph18115930
62. World Health Organization et al. World Health Organization Global recommendations on physical activity for health. Geneva, Switzerland: WHO; 2010. International Journal of Movement Science and Rehabilitation. ISSN-2674-9181
63. Qin F, Song Y, Nassis GP, et al. Prevalence of insufficient physical activity, sedentary screen time and emotional well-being during the early days of the 2019 novel coronavirus (COVID-19) outbreak in China: a national cross-sectional study. SSRN Electron J. Jan 2020. doi:10.2139/ssrn.3566176
64. Lara B, Carnes A, Dakterzada F, et al. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer's disease during the COVID-19 lockdown. Eur J Neurol. 2020;27(9):1744-7. doi:10.1111/ene.14339. Epub 25 May 2020.
65. Canevelli M, Valletta M, Toccaceli Blasi M, et al. Facing Dementia During the COVID-19 Outbreak. J Am Geriatr Soc. 2020 Aug;68(8):1673-6. doi:10.1111/jgs.16644. Epub 2020 Jun 9.
66. Vernuccio L, Sara D, Inzerillo F, et al. Effect of COVID-19 quarantine on cognitive, functional and neuropsychiatric symptoms in patients with mild cognitive impairment and dementia. Aging Clin Exp Res. 2022 May;34(5):1187-94. doi:10.1007/s40520-022-02113-z. Epub 2022 Mar 24.
67. Cudjoe TKM, Kotwal AA. “Social Distancing” Amid a Crisis in Social Isolation and Loneliness. J Am Geriatr Soc. 2020 Jun;68(6):E27-E29. doi:10.1111/jgs.16527. Epub 2020 May 15.
68. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 Sep 3;300(9):1027-37. doi:10.1001/jama.300.9.1027. Erratum in: JAMA. 2009 Jan 21;301(3):276.
69. Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch Intern Med. 2012 Apr 23;172(8):666-8. doi:10.1001/archinternmed.2012.379. Erratum in: Arch Intern Med. 2013 Aug 12;173(15):1477.
70. Varela S, Ayan C, Cancela JM, Martin V. Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: a randomized pilot study. Clin Rehabil. 2012 May;26(5):442-50. doi:10.1177/0269215511425835. Epub 2011 Nov 24.
71. Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One. 2013 Apr 9;8(4):e61483. doi:10.1371/journal.pone.0061483
72. Rehfeld K, Lüders A, Hökelmann A, et al. Dance training is superior to repetitive physical exercise in inducing brain plasticity in the elderly. PLoS One. 2018 Jul 11;13(7):e0196636. doi:10.1371/journal.pone.0196636
73. Chaabene H, Prieske O, Herz M, et al. Home-based exercise programmes improve physical fitness of healthy older adults: A PRISMA-compliant systematic review and meta-analysis with relevance for COVID-19. Ageing Res Rev. 2021 May;67:101265. doi:10.1016/j.arr.2021.101265. Epub 2021 Feb 8.
74. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii: rukovodstvo dlya vrachey [Dementia: a guide for physicians]. Moscow: MEDpressinform; 2010. 272 p. (In Russ.)
75. Gavrilova SI. Farmakoterapiya bolezni Al’tsgeymera [Pharmacotherapy of Alzheimer's disease]. Moscow: Pul’s; 2003. 319 p. (In Russ.)
76. Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7162-6. doi:10.1073/pnas.92.16.7162
77. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine – results of a phase II double-blind study. Pharmacopsychiatry. 1988 May;21(3):144-6. doi:10.1055/s-2007-1014666
78. Reisberg B, Doody R, Stöffler A, et al; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi:10.1056/NEJMoa013128
79. Van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006 May;14(5):428-37. doi:10.1097/01.JGP.0000203151.17311.38
80. Uspenskaya OV, Yakhno NN. The effect of memantine on the cognitive functions of patients with the amnesic variant of the syndrome of moderate cognitive impairment (clinical-psychological and neurochemical study). Nevrologicheskiy zhurnal. 2009;14(3):49-54 (In Russ.)
81. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, et al. Efficacy of Akatinol Memantine in patients with non-dementia cognitive disorders. Results of multicenter clinical observation. Nevrologicheskiy zhurnal. 2010;15(2):52-8 (In Russ.)
82. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341-8. doi:10.4088/jcp.v69n0302
83. Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol. 2020 Nov;92(11):2341-2. doi:10.1002/jmv.26030. Epub 2020 Jun 2.
84. Balli N, Kara E, Demirkan K. The another side of COVID-19 in Alzheimer's disease patients: Drug-drug interactions. Int J Clin Pract. 2020 Oct;74(10):e13596. doi:10.1111/ijcp.13596
Review
For citations:
Starchina Y.A., Kosivtsova O.V. Cognitive impairment in patients with coronavirus infection. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):96-102. (In Russ.) https://doi.org/10.14412/2074-2711-2022-4-96-102
Views: 462
Email this article 